Physician profile
Christopher L Nelson
NPI 1720376825
$309,014.33
in general payments reported to CMS, 2019-2025
35 companies · $41K in 2025
The $41K reported for 2025 was more than what 99% of Acute Care (Nurse Practitioner) providers received nationally (typical 2025 total: $151).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $69K · 2022: $95K · 2023: $60K · 2024: $43K · 2025: $41K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $86K · Travel and Lodging: $49K · Consulting Fee: $4,779 · Food and Beverage: $4,209 · Education: $506.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $85,955.25 |
| Travel and Lodging | $48,941.36 |
| Consulting Fee | $4,779.00 |
| Food and Beverage | $4,208.95 |
| Education | $505.78 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Incyte Corporation | $66,236.78 | 2021-2025 | Jakafi, Jakafi, Monjuvi |
| Amgen INC. | $49,194.24 | 2021-2024 | Kyprolis, Nplate, Lumakras |
| Rigel Pharmaceuticals, INC. | $38,796.10 | 2021-2023 | Tavalisse, Rezlidhia |
| Beigene USA, INC. | $37,239.06 | 2021-2024 | Brukinsa |
| E.R. Squibb & Sons, L.L.C. | $32,535.46 | 2021-2025 | Reblozyl, Opdivo, Opdualag |
| Janssen Biotech, INC. | $28,413.45 | 2024-2025 | Carvykti, Rybrevant, Akeega |
| Astrazeneca Pharmaceuticals Lp | $17,678.03 | 2021-2025 | Tagrisso, Imfinzi |
| Abbvie INC. | $10,409.91 | 2021-2025 | |
| Celgene Corporation | $8,149.72 | 2021-2025 | Reblozyl, Pomalyst |
| Gilead Sciences, INC. | $7,255.07 | 2022 | |
| Hologic Sales and Service, LLC | $4,410.00 | 2023 | |
| Epizyme, INC. | $3,264.30 | 2021 | |
| Merck Sharp & Dohme LLC | $3,224.35 | 2022-2025 | Keytruda, Lynparza |
| Genzyme Corporation | $675.75 | 2021-2025 | |
| Daiichi Sankyo INC. | $199.98 | 2024-2025 | Enhertu |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alexion Pharmaceuticals, INC. | $185.44 | 2025 | Ultomiris |
| Tg Therapeutics, INC. | $185.00 | 2021 | |
| Astellas Pharma US INC | $142.41 | 2023-2025 | Xtandi, Vyloy, Padcev |
| Takeda Pharmaceuticals U.S.A., INC. | $116.95 | 2022-2024 | Hyqvia |
| Sanofi-Aventis U.S. LLC | $99.99 | 2025 | |
| Pfizer INC. | $95.16 | 2023-2025 | |
| Novartis Pharmaceuticals Corporation | $89.91 | 2024-2025 | |
| Caris Mpi, INC. | $57.87 | 2025 | Mi Cancer Seek |
| Aveo Pharmaceuticals, INC. | $54.85 | 2023-2025 | Fotivda |
| Eisai INC. | $53.13 | 2024-2025 | |
| Iovance Biotherapeutics, INC. | $47.08 | 2025 | Amtagvi |
| Myriad Genetic Laboratories, INC. | $38.34 | 2023 | Precisetumor |
| Ipsen Biopharmaceuticals, INC | $35.30 | 2023-2024 | Onivyde, Tazverik |
| Pharmacyclics LLC, An Abbvie Company | $27.41 | 2023 | Imbruvica |
| Stemline Therapeutics INC. | $20.09 | 2025 | Orserdu |
| Bayer Healthcare Pharmaceuticals INC. | $18.70 | 2025 | |
| Seagen INC. | $18.41 | 2023 | Adcetris |
| Tactile Systems Technology INC | $15.73 | 2024 | Entre Plus, Flexitouch Plus |
| Array Biopharma INC | $15.58 | 2024 | Braftovi, Tukysa, Mektovi |
| Genentech USA, INC. | $14.78 | 2023 | Tecentriq |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christopher Nelson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.